HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Details “Quality Agreements” For Marketers, Contract Manufacturers

This article was originally published in The Tan Sheet

Executive Summary

The “Contract Manufacturing Arrangements for Drugs: Quality Agreements” draft guidance describes how parties involved in contract manufacturing of drugs can employ quality agreements to delineate their responsibilities and ensure drug quality, safety and efficacy.

You may also be interested in...



OTC Drug Manufacturer Warned On GMP Problems FDA Initially Found In 2010

"In response to each of those inspections and compliance actions taken against your firm, you proposed specific remediations to fully address the violations," says FDA in warning letter to TG United. Firm in 2013 recalled 44 products – totaling some 688,000 containers plus 2.53m pills or tablets distributed in bulk – due to GMP deviations.

People In Brief

Herbalife brings on Dentali as botanical sciences VP; NACDS expands Nicholson’s role; Innophos announces interim CFO; George Hamilton new face of Infusion Life Sciences; Aker BioMarine names sales VP; Atteryd to chair Food Supplements Europe.

FDA Details “Quality Agreements” For Marketers, Contract Manufacturers

The “Contract Manufacturing Arrangements for Drugs: Quality Agreements” draft guidance describes how parties involved in contract manufacturing of drugs can employ quality agreements to delineate their responsibilities and ensure drug quality, safety and efficacy.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel